Julie Appleby, Kaiser Health News Use Our Content
This Kaiser Health News story might be republished totally free (details).
Early final winter, Pfizer launched its new rheumatoid arthritis therapy, Inflectra, pricing it 15 % beneath the $four,000-a-dose wholesale value of Remicade, the drug for which it’s a shut copy.
Pfizer figured its lower cost would appeal to cost-conscious insurers.
A 12 months later, although, its drug has barely scratched the market and Pfizer has filed an antitrust suit in opposition to its rivals, alleging they’re thwarting lower-priced competitors via “exclusionary contracts” and rebates.
The consequence of the case — filed in September in U.S. District Court in opposition to Johnson & Johnson, the maker of Remicade, and Janssen Biotech — may have an effect on the way forward for biosimilars, a brand new class of medication. Some coverage consultants say these near-copies of biologics are key to slowing spending on advanced and costly specialty medicines like these used to deal with rheumatoid arthritis.
At the guts of the case are rebates, that are reductions off the wholesale value of medication.
Manufacturers provide them to assist maintain their merchandise on insurers’ lists of lined medication. The cash primarily goes again to insurers and pharmacy profit managers, who say the rebates assist cut back well being care spending.
But Pfizer alleges that these rebates are getting used to thwart biosimilars’ entry into the marketplace.
“This is the first antitrust case we’ve seen like this around biosimilars,” stated Michael Carrier, a Rutgers Law School professor “Pfizer is claiming that one form of anti-competitive behavior involves withholding rebates from insurers.”
Subscribe to KHN’s free Morning Briefing.
Sign Up Please affirm your electronic mail handle beneath: Sign Up
Biosimilars are expensive to provide, so they don’t seem to be more likely to set off the identical sharp pricing drop triggered by generics. Still, their producers say they may carry customers some reduction to rival biologics’ excessive value tags.
Pfizer’s Inflectra is without doubt one of the first biosimilars to hit the market since Congress handed laws in 2010 to pave the best way.
According to Pfizer, weeks after Inflectra gained Food and Drug Admininstration approval, J&J moved to stake out its biologic turf.
J&J started requiring insurers and PBMs to signal “exclusionary contracts … designed to block both insurers from reimbursing and hospitals and clinics from purchasing Inflectra or other biosimilars of Remicade despite their lower pricing,” alleges the case filed in federal district court docket in Philadelphia.
If insurers don’t conform to the J&J contracts, the lack of rebates may “for some insurers, run into the tens of millions of dollars annually,” the Pfizer case alleges.
Even with its lower cost, Pfizer confronted an uphill battle to win market share.
Remicade is the fifth-biggest-selling drug by income within the U.S., reaping greater than $four.eight billion in 2016 for makers J&J and Janssen, the swimsuit stated. Often, sufferers are reluctant to change as soon as they’re established on an RA drug that’s working for them.
Still, Pfizer thought it could decide up newly recognized sufferers and achieve floor that manner. But its lawsuit says the drug accounted for less than about four % of whole gross sales, with Remicade getting the remainder, by early September.
“We stand by our contracts,” stated J&J and Janssen Biotech in a written statement. The companies additionally defend rebates as “competition that is doing what competition is meant to do: driving deeper discounts that will lead to overall lower costs.”
Yet the worth of Remicade has not fallen, the Pfizer case says.
Since approval of Inflectra, J&J has raised the listing value of Remicade by near 9 %, the lawsuit alleges. As of September, Remicade’s common gross sales value –after reductions and rebates — is greater than 10 % larger than Inflectra.
“This case is a big deal, because it has the potential to bring to light some of the anti-competitive contracting practices at work to keep … prices extremely high,” stated Jaime King, a professor at University of California-Hastings College of the Law.
Kaiser Health News (KHN) is a nationwide well being coverage information service. It is an editorially impartial program of the Henry J. Kaiser Family Foundation which isn’t affiliated with Kaiser Permanente.